

Gout - Pipeline Insight, 2021

<https://marketpublishers.com/r/GFD10DBB6894EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: GFD10DBB6894EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Gout - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Gout Understanding

Gout: Overview

Gout is a common and complex inflammatory arthritis which is characterized by sudden, severe attack of pain in the joints. The disease is caused due to a condition known as hyperuricemia, where there is excess amount of uric acid (a waste material) in the body. Too much uric acid can build up urate crystals that accumulate in the joints, causing inflammation, and intense pain of gout. Presence of excess levels of uric acid in the body can be either due to breakdown of purines which are found in body as well as food that is consumed or insufficient excretion by kidneys. Individuals with diabetes, poor kidney function, metabolic syndrome, obesity are likely to develop hyperuricemia which causes gout. Also, males are more prone to develop gout primarily because women tend to have lower level of uric acid. Joints that are commonly affected include ankles, knees, and the lesser toe joints.

“Gout - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.

Gout Emerging Drugs Chapters

This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gout Emerging Drugs

SEL 212: Selecta Biosciences

Selecta Bioscience’s lead drug candidate, SEL 212, is a novel combination product consisting of pegadricase (also known as pegsiticase) co-administered with synthetic vaccine particles encapsulating rapamycin (SVP-R). The drug has demonstrated good efficacy and was well tolerated in its phase II trials and is currently being evaluated for the chronic gout in its phase III trials.

URC 102: JW Pharmaceuticals

JW Pharmaceuticals “breakthrough” drug UC-102 is currently being evaluated for the treatment of gout and has demonstrated good safety and efficacy profile in phase II trials. ULC-102 is an antigout small molecule with SLC22A12 protein inhibition

mechanism of action and promotes uric acid excretion.

Further product details are provided in the report.....

Gout: Therapeutic Assessment

This segment of the report provides insights about the different Gout drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gout

There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gout: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.

Gout Report Insights

Gout Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Gout Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Gout drugs?

How many Gout drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gout?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gout therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Gout and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Selecta Biosciences

JW Pharmaceuticals

Astrazeneca

Revive Therapeutics

Fuji Yakuhin Co., Ltd.

ArthroSi Therapeutics

Key Products

SEL 212

URC 102

Verinurad

AR882

FYU-981

Contents

Introduction

Executive Summary

Gout: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Gout – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Gout companies' collaborations, Licensing, Acquisition -Deal Value Trends

Gout Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

SEL 212: Selecta Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

URC-102: JW Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Gout Key Companies

Gout Key Products

Gout- Unmet Needs

Gout- Market Drivers and Barriers

Gout- Future Perspectives and Conclusion

Gout Analyst Views

Gout Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Gout
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Gout
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Gout - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/GFD10DBB6894EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFD10DBB6894EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970